Personalized FGF21 Secretion Optimization System

Publication ID: 24-11857579_0005_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized FGF21 Secretion Optimization System,” Published Technical Disclosure No. 24-11857579_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857579_0005_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,579.

Summary of the Inventive Concept

A next-generation system for optimizing FGF21 secretion through personalized microorganism selection, genetic analysis, and real-time monitoring, enabling targeted FGF21 delivery and enhanced overall health.

Background and Problem Solved

The original patent disclosed a composition for promoting FGF21 secretion using Bifidobacterium breve M-16V. However, this approach has limitations, as it is a one-size-fits-all solution that does not account for individual genetic profiles or gut microbiome compositions. The new inventive concept addresses this limitation by introducing a personalized system that tailors FGF21 secretion optimization to each individual's unique characteristics.

Detailed Description of the Inventive Concept

The system comprises a microorganism repository, a genetic analyzer, and a recommendation engine. The microorganism repository stores multiple strains of Bifidobacterium, each with distinct FGF21 secretion-promoting capabilities. The genetic analyzer assesses the subject's genetic profile, and the recommendation engine selects the optimal Bifidobacterium strain based on this analysis. The system can also integrate real-time FGF21 monitoring using wearable devices, enabling continuous optimization and refinement of the FGF21 secretion-promoting strategy. Additionally, the system can be used to design novel Bifidobacterium strains with enhanced FGF21 secretion-promoting capabilities through computer-aided genetic design and simulation.

Novelty and Inventive Step

The new claims introduce a paradigm shift in FGF21 secretion optimization by incorporating personalized genetic analysis, machine learning algorithms, and real-time monitoring. This approach is distinct from the original patent's composition-based approach and provides a more targeted and effective solution for promoting FGF21 secretion.

Alternative Embodiments and Variations

Alternative embodiments of the system could include the use of different microorganisms, such as Lactobacillus or Streptococcus, or the integration of additional data sources, such as gut microbiome composition or environmental factors. The system could also be adapted for use in various industries, including pharmaceuticals, nutrition, and wellness.

Potential Commercial Applications and Market

The personalized FGF21 secretion optimization system has significant commercial potential in the healthcare and wellness industries, particularly in the areas of metabolic disorders, weight management, and anti-aging. The system could be marketed as a premium service or product, offering individuals a tailored solution for optimizing their FGF21 secretion and overall health.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Microbiome biotechnology, specifically focused on probiotic strain selection, genetic analysis, and metabolic biomarker modulation (FGF21 secretion)

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in microbiology, biotechnology, or bioengineering, possessing expertise in microorganism genetic manipulation, metabolic pathway analysis, and personalized health technologies

Obviousness Rationale

A PHOSITA would recognize that the personalized FGF21 optimization system represents a predictable technological progression from the source patent's foundational work on Bifidobacterium strain-mediated metabolic modulation. The PTD's systematic approach of genetic profiling, strain selection, and real-time monitoring naturally extends the source patent's core methodology of using specific bacterial strains to influence physiological processes. The integration of machine learning and personalized genetic analysis would be considered an obvious enhancement given the rapid technological developments in precision medicine and microbiome research.

Obvious Combinations & Variations

Source Patent Element

Bifidobacterium breve M-16V strain for metabolic modulation

PTD Variation

Expanded microorganism repository with multiple Bifidobacterium strains and genetic selection algorithm

Obviousness Reasoning

A PHOSITA would recognize that expanding strain selection through systematic genetic analysis is a predictable optimization of the original patent's single-strain approach, representing a standard technique in microbial biotechnology

Source Patent Element

Method of administering Bifidobacterium in food or pharmaceutical compositions

PTD Variation

Real-time FGF21 monitoring system with wearable sensor technology

Obviousness Reasoning

Continuous physiological monitoring is a known technique in personalized medicine, and integrating such monitoring with probiotic administration represents an obvious technological progression

Source Patent Element

Metabolic modulation through specific bacterial strain administration

PTD Variation

Computer-implemented genetic design for engineering enhanced Bifidobacterium strains

Obviousness Reasoning

Rational strain engineering using computational methods is a standard approach in biotechnology, representing a predictable extension of existing strain selection techniques

Source Patent Element

Composition for promoting FGF21 secretion

PTD Variation

Machine learning algorithms for predicting FGF21 secretion based on gut microbiome composition

Obviousness Reasoning

Applying computational predictive techniques to biological data represents a standard approach in contemporary biotechnology research, with predictable outcomes for skilled practitioners

Source Patent Element

Method of administering Bifidobacterium to modulate physiological processes

PTD Variation

Engineered strains responsive to specific environmental cues for targeted FGF21 delivery

Obviousness Reasoning

Developing environmentally responsive bacterial strains is a known technique in synthetic biology, representing an obvious technological progression for skilled researchers

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857579 and the comprehensive technological extensions disclosed herein, a person of ordinary skill in the art would find the claimed innovations of personalized FGF21 optimization systems to be obvious variations that do not meet the non-obviousness requirements of 35 U.S.C. § 103, thereby rendering such claims unpatentable as anticipated prior art.

Original Patent Information

Patent Number	US 11,857,579
Title	Composition for promoting the secretion of FGF21
Assignee(s)	Morinaga Milk Industry Co., Ltd.